Mikhail Blagosklonny currently works at the Roswell Park Cancer Institute. He is the Professor of Oncology. He is a famous scientist specialized in the study of Aging as well as Cancer. He attended the First Pavlov State Medical University of St. Petersburg. His studies at the institution earned a master’s degree in the study if Internal Medicine. He also holds a Ph.D. from the same University in Experimental Medicine and Cardiology.
In the year 2002, Mikhail was promoted to the position of associate professor of medicine at the New York Medical College. The college is located in Valhalla in New York. Later on, he moved to Ordway Research Institute. Mikhail Blagosklonny served in the position of the senior scientist at the Institute. In the year 2009, he went to Roswell Park Cancer Institute to occupy the position of the Professor of Oncology. His possession of skills as well as experience obtained from numerous places where he had served transformed him into an excellent professor. The interest of his study entails a lot. Such includes anti-aging drugs, cancer, Biogerontology as well as the besieged treatments that prevent the healthy cells from damage. Read more on templeofthecave.com
Mikhail serves as the editor-in-chief of Oncotarget as well as Cell Cycle. This is in addition to being the associate editor of cancer biology as well as therapy. Mikhail Blagosklonny is one of the editorial board members working on the Death and Differentiation of the Cell. He has also developed a theory in line with the importance of TOR Signaling potential when dealing with cancer as well as aging.
He utilized the Rapamycin in the course of his proposal. The drug is commonly used during cancer treatment process. His suggestion was that the drug is a potential treatment towards lie extensions.
According to the categories, he has been classified as being among the leading fanatical supporters of Rapamycin in lifelong research. His research varies from molecular and cellular biology to clinical investigations. It entails anticancer therapeutics, drug resistance for healthy cells, mitosis, oncogenesis, apoptosis, signal transduction, cell cycle, selective protection, as well as tumor suppressors.
He is also a writer of the theory of the aging hyperfunction. This is in addition to being an author of cell chemotherapeutic and cyclotherapy engineering. Mikhail is famous for having a lot of curiosity towards oncology.
It is for this reason that he has confidence in the possibility of managing aging as well as cancer. His other belief is the possibility of treating cancer and thus the reason behind the proposal of Rapamycin. He has written 30 research articles, book reviews, as well as chapters whose publication is under his name. Check Mikhail’s profile in LinkedIn
Also, he is the PLOS ONE’s associate editor. This is the American Journal of Pathology and International Journal of Cancer. The reason behind his success in being among the leading Oncology researchers globally is commitment and hard work. He loves humanity, and it is for this reason that he entered his work field with the objecting of facilitating the achievement of a society free from diseases.